Guido Oelkers - Swedish Orphan CEO Pres
| B6E Stock | EUR 26.48 0.04 0.15% |
Insider
Guido Oelkers is CEO Pres of Swedish Orphan Biovitrum
| Age | 58 |
| Phone | 46 86 97 20 00 |
| Web | https://www.sobi.com |
Swedish Orphan Management Efficiency
The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Polzer | Zoetis Inc | 54 | |
| Parag Agarwal | Dr Reddys Laboratories | 57 | |
| Ricky Hopson | Catalent | 47 | |
| Aymeric Chatelier | Ipsen SA | 54 | |
| Francois Garnier | Ipsen SA | 61 | |
| Julien Meissonnier | Catalent | N/A | |
| Wafaa Mamilli | Zoetis Inc | 56 | |
| Christophe Weber | Takeda Pharmaceutical | 57 | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Gary Hendler | Eisai Co | 57 | |
| MD FAAN | Eisai Co | 73 | |
| Charles Lickfold | Catalent | 49 | |
| Iwaaki Taniguchi | Takeda Pharmaceutical | N/A | |
| Kazuhiro Hatanaka | Shionogi Co | N/A | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
| Regis Mulot | Ipsen SA | 57 | |
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Akira Kato | Shionogi Co | N/A | |
| Kenta Takahashi | Eisai Co | 64 | |
| Ryuichi Kiyama | Shionogi Co | N/A | |
| Kare Schultz | Teva Pharmaceutical Industries | 62 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 |
Swedish Orphan Biovitrum Leadership Team
Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Konstantina Karampela, Director Operations | ||
| Christine Wesstrom, Head Operations | ||
| Guido Oelkers, CEO Pres | ||
| Thomas Larsen, Head Relations | ||
| Pablo Mora, Head Access | ||
| Armin MD, Head Affairs | ||
| Philip Wood, Head Haematology | ||
| Anders MD, Head Officer | ||
| Torbjrn Hallberg, G HR | ||
| Daniel Rankin, Head Devel | ||
| Henrik Stenqvist, Chief Officer |
Swedish Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 6.67 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 69.59 % | |||
| Price To Earning | 18.28 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 3.66 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Swedish Stock
Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.